Tags

Type your tag names separated by a space and hit enter

Simvastatin monotherapy as a potential option for statin-associated muscle symptoms: a case report.
J Clin Pharm Ther. 2016 Oct; 41(5):568-71.JC

Abstract

WHAT IS KNOWN AND OBJECTIVES

Choosing an alternative statin is recommended when managing statin-associated muscle symptoms (SAMS) and new hydrophilic statins are often suggested. We report on a case of statin-associated muscle damage that was successfully managed by simplifying the patient's combination therapy with simvastatin-ezetimibe to simvastatin alone.

CASE SUMMARY

The patient experienced SAMS when he was successively treated with atorvastatin, rosuvastatin, Xuezhikang capsule and combined simvastatin/ezetimibe therapy. However, the patient tolerated simvastatin therapy well even at a dose of 40 mg/day.

WHAT IS NEW AND CONCLUSION

Our case suggests that patients with SAMS who are intolerant to a wide variety of statins may be successfully managed with simvastatin monotherapy.

Authors+Show Affiliations

China Heart Institute of Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China. Graduate School of Beijing University of Traditional Chinese Medicine, Beijing, China.China Heart Institute of Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China. Graduate School of China Academy of Chinese Medical Sciences, Beijing, China.China Heart Institute of Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China. Graduate School of Beijing University of Traditional Chinese Medicine, Beijing, China. Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing, China.China Heart Institute of Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China. Graduate School of Beijing University of Traditional Chinese Medicine, Beijing, China. Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing, China.China Heart Institute of Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China. Graduate School of Beijing University of Traditional Chinese Medicine, Beijing, China. Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing, China.China Heart Institute of Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China.China Heart Institute of Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China. Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing, China.

Pub Type(s)

Case Reports

Language

eng

PubMed ID

27425755

Citation

Qu, H, et al. "Simvastatin Monotherapy as a Potential Option for Statin-associated Muscle Symptoms: a Case Report." Journal of Clinical Pharmacy and Therapeutics, vol. 41, no. 5, 2016, pp. 568-71.
Qu H, Guo M, Kou N, et al. Simvastatin monotherapy as a potential option for statin-associated muscle symptoms: a case report. J Clin Pharm Ther. 2016;41(5):568-71.
Qu, H., Guo, M., Kou, N., Wu, H. T., Zhang, Y., Gao, Z. Y., & Shi, D. Z. (2016). Simvastatin monotherapy as a potential option for statin-associated muscle symptoms: a case report. Journal of Clinical Pharmacy and Therapeutics, 41(5), 568-71. https://doi.org/10.1111/jcpt.12419
Qu H, et al. Simvastatin Monotherapy as a Potential Option for Statin-associated Muscle Symptoms: a Case Report. J Clin Pharm Ther. 2016;41(5):568-71. PubMed PMID: 27425755.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Simvastatin monotherapy as a potential option for statin-associated muscle symptoms: a case report. AU - Qu,H, AU - Guo,M, AU - Kou,N, AU - Wu,H-T, AU - Zhang,Y, AU - Gao,Z-Y, AU - Shi,D-Z, Y1 - 2016/07/18/ PY - 2016/02/20/received PY - 2016/06/14/accepted PY - 2016/7/19/entrez PY - 2016/7/19/pubmed PY - 2017/4/27/medline KW - alternative statin KW - simvastatin KW - statin-associated muscle symptoms SP - 568 EP - 71 JF - Journal of clinical pharmacy and therapeutics JO - J Clin Pharm Ther VL - 41 IS - 5 N2 - WHAT IS KNOWN AND OBJECTIVES: Choosing an alternative statin is recommended when managing statin-associated muscle symptoms (SAMS) and new hydrophilic statins are often suggested. We report on a case of statin-associated muscle damage that was successfully managed by simplifying the patient's combination therapy with simvastatin-ezetimibe to simvastatin alone. CASE SUMMARY: The patient experienced SAMS when he was successively treated with atorvastatin, rosuvastatin, Xuezhikang capsule and combined simvastatin/ezetimibe therapy. However, the patient tolerated simvastatin therapy well even at a dose of 40 mg/day. WHAT IS NEW AND CONCLUSION: Our case suggests that patients with SAMS who are intolerant to a wide variety of statins may be successfully managed with simvastatin monotherapy. SN - 1365-2710 UR - https://www.unboundmedicine.com/medline/citation/27425755/Simvastatin_monotherapy_as_a_potential_option_for_statin_associated_muscle_symptoms:_a_case_report_ L2 - https://doi.org/10.1111/jcpt.12419 DB - PRIME DP - Unbound Medicine ER -